In a report released yesterday, Kostas Biliouris from BMO Capital maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), with a price target of $200.00.
Kostas Biliouris has given his Buy rating due to a combination of factors that suggest a positive outlook for Sarepta Therapeutics. Despite the temporary clinical hold on Elevidys trials in the EU due to a patient death, this is seen as a standard procedure that is unlikely to significantly impact the overall Elevidys program. The trials on hold are not central to the Elevidys narrative, and the potential for approval and revenue growth in the US remains strong.
Additionally, Sarepta’s expertise in Duchenne Muscular Dystrophy (DMD) and its established market presence provide a solid foundation for future growth. The company’s gene therapy portfolio, which targets a significant portion of Limb-Girdle Muscular Dystrophy (LGMD) patients, offers further growth potential. With no significant competitors in the near term, Sarepta is well-positioned to capitalize on its market leadership and drive revenue growth.
In another report released today, Needham also maintained a Buy rating on the stock with a $183.00 price target.
SRPT’s price has also changed dramatically for the past six months – from $122.520 to $62.470, which is a -49.01% drop .